» Articles » PMID: 37996417

Molecular EPISTOP, a Comprehensive Multi-omic Analysis of Blood from Tuberous Sclerosis Complex Infants Age Birth to Two Years

Abstract

We present a comprehensive multi-omic analysis of the EPISTOP prospective clinical trial of early intervention with vigabatrin for pre-symptomatic epilepsy treatment in Tuberous Sclerosis Complex (TSC), in which 93 infants with TSC were followed from birth to age 2 years, seeking biomarkers of epilepsy development. Vigabatrin had profound effects on many metabolites, increasing serum deoxycytidine monophosphate (dCMP) levels 52-fold. Most serum proteins and metabolites, and blood RNA species showed significant change with age. Thirty-nine proteins, metabolites, and genes showed significant differences between age-matched control and TSC infants. Six also showed a progressive difference in expression between control, TSC without epilepsy, and TSC with epilepsy groups. A multivariate approach using enrollment samples identified multiple 3-variable predictors of epilepsy, with the best having a positive predictive value of 0.987. This rich dataset will enable further discovery and analysis of developmental effects, and associations with seizure development in TSC.

Citing Articles

Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight.

Klein P, Friedman D, Kwan P CNS Drugs. 2024; 38(12):949-960.

PMID: 39433725 DOI: 10.1007/s40263-024-01130-y.


A multicenter, matched case-control analysis comparing burden of illness among patients with tuberous sclerosis complex related epilepsy, generalized idiopathic epilepsy, and focal epilepsy in Germany.

Lappe L, Hertzberg C, Knake S, Knuf M, von Podewils F, Willems L Neurol Res Pract. 2024; 6(1):29.

PMID: 38812055 PMC: 11138101. DOI: 10.1186/s42466-024-00323-6.


Molecular EPISTOP, a comprehensive multi-omic analysis of blood from Tuberous Sclerosis Complex infants age birth to two years.

Huschner F, Glowacka-Walas J, Mills J, Klonowska K, Lasseter K, Asara J Nat Commun. 2023; 14(1):7664.

PMID: 37996417 PMC: 10667269. DOI: 10.1038/s41467-023-42855-6.

References
1.
Durinck S, Spellman P, Birney E, Huber W . Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 2009; 4(8):1184-91. PMC: 3159387. DOI: 10.1038/nprot.2009.97. View

2.
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

3.
Curatolo P, Specchio N, Aronica E . Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy. Lancet Neurol. 2022; 21(9):843-856. DOI: 10.1016/S1474-4422(22)00213-7. View

4.
Cox J, Neuhauser N, Michalski A, Scheltema R, Olsen J, Mann M . Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 2011; 10(4):1794-805. DOI: 10.1021/pr101065j. View

5.
de Vries P, Whittemore V, Leclezio L, Byars A, Dunn D, Ess K . Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol. 2014; 52(1):25-35. PMC: 4427347. DOI: 10.1016/j.pediatrneurol.2014.10.004. View